Table 2.

Blood pressure characteristics of SPRINT (Systolic Blood Pressure Intervention Trial) participants in the ambulatory blood pressure ancillary study by orthostatic hypotension history at the 6-, 12-, or 24-month SPRINT study visit, mean (SD) or %

Variable	Total	Orthostatic hypotension at least once during 6-, 12-, and 24-month visits	No occurrence of orthostatic hypotension
	N = 897	N = 128	N = 769
Clinic SBP, mm Hg (27-mo)	127.6 (15.6)	129.2 (17.1)	127.4 (15.3)
Clinic DBP, mm Hg (27-mo)	69.7 (12.0)	69.7 (13.1)	69.7 (11.8)
White coat effect, %	8.3	14.8	7.2
Dipping status, %
Extreme dipper	10.3	3.1	11.4
Dipper	35.3	28.1	36.5
Nondipper	38.8	43.8	38.0
Reverse dipper	15.6	25.0	14.0
BP phenotypes, %
White coat hypertension	5.7	10.2	4.9
Masked hypertension	26.2	25.0	26.4
Controlled hypertension	51.1	48.4	51.6
Sustained hypertension	17.0	16.4	17.1
N antihypertensive medications (27-mo)	2.3 (1.3)	2.4 (1.3)	2.3 (1.3)

24-mo, data collected at 24-month annual visit; 27-mo, data collected at 27-month study visit. Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; N antihypertensive medication, number of antihypertensive medications; SBP, systolic blood pressure. Participant BP phenotypes were defined as follows: (i) white-coat hypertension (clinic BP ≥140/90 mm Hg and daytime ambulatory BP <135/85 mm Hg), (ii) masked hypertension (clinic BP <140/90 mm Hg and daytime ambulatory BP ≥135/85 mm Hg), (iii) controlled hypertension (clinic BP <140/90 mm Hg and daytime ambulatory BP <135/85 mm Hg), and (iv) sustained hypertension (clinic BP ≥140/90 mm Hg and daytime ambulatory BP ≥135/85 mm Hg).